# Trace Neuroscience

> Trace Neuroscience is a South San Francisco biopharmaceutical company developing genomic medicines for neurodegenerative diseases, starting with ALS. Its lead program, TRCN-1023, is an antisense oligonucleotide designed to restore UNC13A protein function - a target genetically validated in roughly 97% of people living with ALS - by correcting the faulty RNA splicing caused by TDP-43 dysfunction. The company launched in November 2024 with a $101 million Series A led by Third Rock Ventures and entered the clinic in 2026.

- **Founded:** 2024
- **Headquarters:** South San Francisco, California, United States
- **Founders:** Eric Green (Co-Founder & CEO), Pietro Fratta (Co-Founder; Professor of Cellular and Molecular Neuroscience, UCL & Francis Crick Institute), Aaron Gitler (Co-Founder; Professor of Genetics, Stanford University), Michael Ward (Co-Founder; Senior Investigator, NINDS / NIH)
- **Team size:** ~21 employees
- **Products:** TRCN-1023, UNC13A genomic platform
- **Notable:** Launched in November 2024 with an oversubscribed $101 million Series A., Named a Fierce Biotech 'Fierce 15' Biotech Company of 2025., Advanced lead candidate TRCN-1023 from concept to the clinic by 2026.

## Products & services

- **TRCN-1023** — Lead antisense oligonucleotide (ASO) for ALS, administered by intrathecal injection. It binds UNC13A messenger RNA to correct mis-splicing and restore UNC13A protein, preserving nerve-muscle communication. Entered clinical development in 2026.
- **UNC13A genomic platform** — A genomic medicine approach targeting the TDP-43 / UNC13A axis, with potential to extend beyond ALS to frontotemporal dementia and Alzheimer's disease.

## Achievements

- Launched in November 2024 with an oversubscribed $101 million Series A.
- Named a Fierce Biotech 'Fierce 15' Biotech Company of 2025.
- Advanced lead candidate TRCN-1023 from concept to the clinic by 2026.
- Secured an exclusive license to foundational UNC13A IP from UCL.
- Launched ALS clinical trials across the UK, Netherlands and China.

## Latest updates

- **2024-11** — Trace Neuroscience launches publicly with a $101M Series A led by Third Rock Ventures and an exclusive UNC13A license from UCL.
- **2025-01** — Named to Fierce Biotech's 'Fierce 15' list of standout biotech companies of 2025.
- **2026-01** — Initiated global clinical development of TRCN-1023 with the FUNCTION ALS Phase 1/2 trial in the UK and Netherlands.
- **2026-06** — First patients dosed in the China-based LAUNCH ALS investigator-initiated trial with partner Tenacia Biopharmaceutical.

## Links

- Website: https://www.traceneuro.com
- LinkedIn: https://www.linkedin.com/company/traceneuro
- Twitter/X: https://x.com/traceneuro

---

Profile page: https://yespress.io/trace-neuroscience
Published by YesPress — https://yespress.io
Last updated: 2026-06-27